Offner, Fritz, Robak, Tadeusz, Janssens, Ann, Babu, K Govind, Kloczko, Janusz, Grosicki, Sebastian, Mayer, Jiri, Panagiotidis, Panagiotis, Schuh, Anna, Pettitt, Andrew et al (show 5 more authors)
(2020)
A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
BRITISH JOURNAL OF HAEMATOLOGY, 190 (5).
pp. 736-740.
![[img]](https://livrepository.liverpool.ac.uk/style/images/fileicons/text.png) |
Text
Minor revision_COMPLEMENT 1 Short report_March 6.docx - Author Accepted Manuscript Download (106kB) |
|
Text
Combined image_OS and PFS for BJH.pdf - Author Accepted Manuscript Download (33kB) | Preview |
Abstract
The Complement 1 trial investigated the efficacy and safety of ofatumumab + chlorambucil with chlorambucil monotherapy in patients with previously untreated chronic lymphocytic leukaemia (CLL). On long-term follow-up in the chemoimmunotherapy arm vs. the chemotherapy arm there was an estimated 12% (not significant) and 39% risk reduction in overall survival and progression-free survival, respectively. A high rate (61%) of treatment with next-line therapies in both the treatment arms may dilute any potential OS difference and confound the interpretation of the OS results. Addition of ofatumumab to chlorambucil demonstrated clinical benefit and tolerability as a frontline treatment option in patients unfit for fludarabine-containing therapy, with no new safety concerns.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | ofatumumab, chlorambucil, Complement 1, anti-CD20 monoclonal antibodies, chronic lymphocytic leukaemia |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 10 Jun 2020 07:47 |
| Last Modified: | 18 Jan 2023 23:49 |
| DOI: | 10.1111/bjh.16625 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3089892 |
Dimensions
Dimensions
